AMOPYROQUIN (PROPOQUIN) IN RHEUMATOID ARTHRITIS

A controlled, double‐blind trial of amopyroquin vs. placebo has been completed in 15 patients with active, classical or definite rheumatoid arthritis. Improvement in all the parameters determined occurred while the patients were on amopyroquin. Grip strength, sedimentation rate, and Lansbury's indices showed statistically significant improvement while on amopyroquin. Improvement in the 50‐foot walk and A.R.A. functional capacity approached statistical significance. Amopyroquin was well tolerated, but asymptomatic elevation of SGOT occurred in four patients and appeared to be related to the drug. Other tests of liver function remained normal. Un controlate essayo a duple anonymato esseva effectuate con amopyroquina contra placebo in un gruppo de 15 patientes con active arthritis rheumatoide classic o definite. Melioration in omne le parametros studiate occurreva durante que le patientes recipeva amopyroquina. Fortia del sasir, sedimentation erythrocytic, e le indices de Lansbury indicava statisticamente significative meliorationes durante le curso de amopyroquina. Melioration in le ambulation de 50 pedes e in le capacitate functional secundo le A.R.A. approchava un grado de signification statistic. Amopyroquina esseva ben tolerate, sed un elevation asymptomatic de transaminase glutamic‐oxaloacetic del sero occurreva in quatro patientes, apparentemente in relation con le pharmaco. Altere tests del function hepatic remaneva normal.